Dr. Houston Holmes, M.D.
What this data tells you about Dr. Holmes
Dr. Houston Holmes is a hematology & oncology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Holmes performed 39,091 Medicare services across 2,706 unique beneficiaries.
Between the years covered by Open Payments, Dr. Holmes received a total of $254,594 from 49 pharmaceutical and/or device companies across 362 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Holmes is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 8,400 | $43 | $137 |
| Anti-nausea injection (fosaprepitant) | 6,150 | $0 | $5 |
| Paclitaxel chemotherapy injection | 5,006 | $0 | $8 |
| Contrast dye for imaging (iodine-based) | 4,111 | $0 | $3 |
| Iron sucrose injection (Venofer) | 3,500 | $0 | $2 |
| Daratumumab injection (Darzalex) | 2,880 | $38 | $126 |
| Dexamethasone injection (steroid) | 1,148 | $0 | $1 |
| Blood draw (venipuncture) | 859 | $8 | $20 |
| Comprehensive metabolic blood panel | 718 | $10 | $64 |
| Complete blood count (CBC) with differential | 676 | $8 | $36 |
| Anti-nausea injection (Aloxi/palonosetron) | 650 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 550 | $0 | $24 |
| Office visit, established patient (30-39 min) | 510 | $93 | $368 |
| Lactate dehydrogenase (enzyme) level | 436 | $6 | $31 |
| Measurement of immunoglobulin light chains | 338 | $17 | $60 |
| Microscopic examination for white blood cells with manual cell count | 249 | $4 | $22 |
| Complete blood count (CBC), automated | 249 | $6 | $34 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 228 | $23 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 198 | $105 | $707 |
| Injection of additional new drug or substance into vein | 162 | $12 | $108 |
| Immunoglobulin level test | 156 | $9 | $56 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 154 | $3 | $373 |
| Injection, carboplatin, 50 mg | 149 | $2 | $300 |
| Injection, fluorouracil, 500 mg | 126 | $2 | $13 |
| Office visit, established patient, complex (40-54 min) | 123 | $136 | $496 |
| Reticulated (young) platelet measurement | 113 | $35 | $143 |
| Ferritin level test (iron stores) | 94 | $13 | $60 |
| Iron level test | 91 | $6 | $27 |
| Iron binding capacity test | 91 | $9 | $35 |
| Injection, magnesium sulfate, per 500 mg | 90 | $1 | $6 |
| Red blood count, automated test | 89 | $4 | $23 |
| Hospital follow-up visit, moderate complexity | 72 | $62 | $247 |
| Injection, zoledronic acid, 1 mg | 72 | $6 | $431 |
| Injection, diphenhydramine hcl, up to 50 mg | 68 | $1 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 63 | $52 | $344 |
| Drug injection, under skin or into muscle | 53 | $11 | $96 |
| Office visit, established patient (20-29 min) | 52 | $53 | $250 |
| Unclassified drugs | 50 | $1 | $8 |
| Hospital follow-up visit, high complexity | 46 | $94 | $357 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $49 | $313 |
| Ct scan of chest with contrast | 40 | $50 | $821 |
| CT scan of abdomen and pelvis with contrast | 37 | $180 | $1,067 |
| Administration of chemotherapy into vein, each additional hour | 37 | $23 | $161 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $58 | $211 |
| Infusion, normal saline solution , 1000 cc | 24 | $2 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 22 | $16 | $94 |
| New patient office visit (45-59 min) | 17 | $127 | $565 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 17 | $85 | $657 |
| New patient office visit, complex (60-74 min) | 15 | $137 | $709 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 14 | $1,096 | $4,802 |
| Initial hospital admission, high complexity | 12 | $136 | $694 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 12 | $135 | $500 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (68%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for hematology & oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Holmes is a mixed practice specialist, with above-average Medicare volume (top 24% in TX), and high industry engagement (speaking/promotional, top 2%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Holmes experienced with pembrolizumab injection (keytruda)?
Does Dr. Holmes receive payments from pharmaceutical companies?
How do Dr. Holmes's costs compare to other hematology & oncologys in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology